M. Bouattour

发表论文 8 篇 · 总被引 30 次 · h-index 2

代表论文

• 56P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC) (2022 · Annals of Oncology · 被引 23)
• LBA51 IKF-035/ABC-HCC: A phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma (2025 · Annals of Oncology · 被引 4)
• 1487P Extended follow-up at 42 months of atezolizumab–bevacizumab in advanced HCC: Insights from the CHIEF prospective study (2025 · Annals of Oncology · 被引 1)
• 102P Potentially prognostic factors of overall survival in advanced biliary tract cancer in the randomised phase III TOPAZ-1 study (2023 · Annals of Oncology · 被引 1)
• Corrigendum to “78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)” (2023 · Annals of Oncology · 被引 1)
• 350P Safety and efficacy of durvalumab plus gemcitabine (gem)-based chemotherapy (chemo) regimens in participants (pts) with advanced biliary tract cancer (aBTC): Primary results from the phase IIIb TOURMALINE study (2026 · Annals of Oncology)